MedPath

FDA Proposes Removal of Oral Phenylephrine as Ineffective Nasal Decongestant

• The FDA is proposing to remove oral phenylephrine from over-the-counter (OTC) cold medications, deeming it ineffective as a nasal decongestant. • This decision follows a review of available data, including historical data and recent studies, which showed phenylephrine was no more effective than a placebo. • The move is influenced by research dating back to the 1970s and petitions from pharmacists who questioned phenylephrine's efficacy, leading to advisory committee meetings. • While products containing phenylephrine remain available, the FDA is seeking public comment until May 7, 2025, before issuing a final order.

The Food and Drug Administration (FDA) has proposed that nonprescription drugs containing oral phenylephrine should be removed from pharmacy shelves, citing its ineffectiveness as a nasal decongestant. This proposal could significantly alter the landscape of over-the-counter (OTC) cold medications, impacting products like Mucinex and Sudafed PE.

Efficacy Concerns

According to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER), this action is based on a thorough review of available data, aligning with the advice of an advisory committee. The review included historical data used to initially support phenylephrine's effectiveness 30 years ago.
Research questioning the efficacy of phenylephrine has been ongoing for many years. An article published in 1993, based on research from the 1970s, suggested that while phenylpropanolamine and pseudoephedrine were effective decongestants, oral phenylephrine was not. More recently, a 2023 review in Cureus found that oral phenylephrine was not significantly more effective than a placebo in alleviating nasal congestion in adults. This systematic review analyzed multiple studies comparing oral phenylephrine to placebo or standard care, assessing their impact on congestion and nasal airway resistance.

The Path to Review

The FDA's reevaluation was spurred by the work of Randy C. Hatton, Pharm.D., and Leslie Hendeles, Pharm.D., from the University of Florida College of Pharmacy. Their research, initiated in 2005, led to two petitions urging the FDA to review the evidence. This culminated in two FDA advisory committee meetings, the most recent in October 2023, where all 16 members voted against the assertion that orally administered phenylephrine is effective as a nasal decongestant.

Historical Context

Phenylephrine's widespread use in nonprescription cold medications increased after 2006, when products containing pseudoephedrine were moved behind pharmacy counters due to its potential use in methamphetamine production. Manufacturers reformulated many cold products with phenylephrine as a substitute.
In a Scientific American article, Hatton highlighted that phenylephrine was initially approved before the 1962 Kefauver-Harris Amendments, which established rigorous clinical trial standards for drug approval. This meant that phenylephrine's initial approval did not require proof of efficacy, relying instead on chemistry studies to demonstrate safety. The FDA established the OTC monograph process 10 years after the 1962 amendment to reconsider products that hadn't been proven effective.

Next Steps

For now, products containing phenylephrine remain available to consumers. The FDA is soliciting public comments on the proposed order until May 7, 2025, after which it will issue a final decision regarding the future of oral phenylephrine in OTC medications.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Moves to Remove Oral Phenylephrine as Decongestant Due to Ineffectiveness

The FDA is moving to phase out oral phenylephrine, a common decongestant in over-the-counter cold medicines, after determining it is no more effective than a placebo.
This decision follows expert reviews of studies dating back to the 1960s, which revealed flaws and questionable data regarding phenylephrine's efficacy in oral form.

FDA Proposes Removal of Oral Phenylephrine from OTC Nasal Decongestants

The FDA is proposing to remove oral phenylephrine from over-the-counter nasal decongestants due to its ineffectiveness.
This decision follows a comprehensive review of clinical data and a unanimous recommendation from the Nonprescription Drug Advisory Committee.

FDA Proposes Ban on Oral Phenylephrine in OTC Decongestants

The FDA has proposed removing oral phenylephrine from over-the-counter decongestants after determining it is no more effective than a placebo.
This decision follows unanimous agreement from an FDA advisory body and years of scientific debate regarding phenylephrine's efficacy.

FDA Proposes Ban on Oral Phenylephrine in OTC Cold Medications Due to Ineffectiveness

The FDA is proposing to remove oral phenylephrine, a common decongestant, from over-the-counter medications due to its lack of proven effectiveness.
Phenylephrine has been used since 1976 and became more prevalent after pseudoephedrine was moved behind pharmacy counters.

FDA Proposes Ban on Oral Phenylephrine Due to Ineffectiveness as Decongestant

The FDA is proposing to remove oral phenylephrine from over-the-counter cold medications due to its ineffectiveness as a nasal decongestant.
The decision follows a review of scientific data, including older determinations and recent research, indicating a lack of efficacy.

FDA Weighs Removal of Oral Phenylephrine; Approves Drugs for CML, Gastric Cancer, and UTIs

The FDA is considering removing oral phenylephrine from its OTC Monograph due to a lack of efficacy as a nasal decongestant, potentially impacting numerous cold and allergy products.
Novartis' Scemblix expands its FDA-approved uses to include the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ PML).

FDA Proposes Ban on Oral Phenylephrine for Cold Relief Due to Ineffectiveness

The FDA is moving to remove oral phenylephrine from the list of approved over-the-counter ingredients due to its lack of efficacy as a nasal decongestant.
Scientific reviews indicate that less than 1% of orally administered phenylephrine is absorbed into the bloodstream, rendering it ineffective.

FDA Proposes Removal of Oral Phenylephrine as Ineffective Decongestant

The FDA has proposed removing oral phenylephrine from the list of approved over-the-counter decongestants due to its lack of efficacy in relieving nasal congestion.
This decision follows a review of available data and advice from an advisory committee, which concluded that oral phenylephrine is not effective as a nasal decongestant.

FDA Proposes Ban on Oral Phenylephrine in Over-the-Counter Decongestants

The FDA is seeking to ban oral phenylephrine in OTC nasal decongestants due to research indicating its ineffectiveness as a pill or syrup.
The proposal follows a review of data, including a September 2023 advisory committee conclusion, questioning phenylephrine's efficacy as a decongestant.

FDA Proposes Removing Oral Phenylephrine from OTC Nasal Decongestants

The FDA is proposing to remove oral phenylephrine as an active ingredient in over-the-counter (OTC) monograph drug products for temporary nasal congestion relief.
This decision follows an FDA review that concluded oral phenylephrine is ineffective in relieving nasal congestion at recommended doses.

Reference News

[1]
FDA Suggests Removing Nonprescription Decongestant from Market
managedhealthcareexecutive.com · Nov 8, 2024

The FDA proposes removing nonprescription drugs containing phenylephrine from shelves due to its ineffectiveness as a na...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy